From: Capecitabine and stereotactic radiation in the management of breast cancer brain metastases
Variable | n | % |
---|---|---|
No. of Patients | 23 | Â |
Treatment Sessions | 31 | Â |
No. of Lesions | 90 | Â |
F/U from RT (months) | ||
 Median (range) | 9.2 (1.9–94.1) |  |
F/U from Brain Metastases Diagnosis (months) | ||
 Median (range) | 20.2 (5.5–96.4) |  |
Age at time of RT | ||
 Median (range) | 56 (40–75) |  |
KPS | ||
 100 | 7 | 30% |
 90 | 8 | 35% |
 80 | 7 | 30% |
 60 | 1 | 4% |
Lesions Treated Per Patient | ||
 Median (range) | 3 (1–12) |  |
Receptor Status | ||
 HR+/HER2- | 7 | 30% |
 HR- /HER2+ | 3 | 13% |
 HR+/HER2+ | 6 | 26% |
 HR−/HER2- | 7 | 30% |
RT in Relation to Capecitabine | ||
 Before | 12 | 39% |
 After | 4 | 13% |
 Concurrent | 15 | 48% |
Interval Between Capecitabine and RT (months) | ||
 Median (range) | 1.5 (0.26–5.5) |  |
Concurrent Therapy with Capecitabine | ||
 None | 7 | 30% |
 Additional Chemotherapy | 8 | 35% |
 Trastuzumab | 2 | 9% |
 Trastuzumab + Chemotherapy | 2 | 9% |
 Trastuzumab + TKI | 2 | 9% |
 Pembrolizumab | 1 | 4% |
 TKI | 1 | 4% |